PC1

ImmunoMet Therapeutics Announces First Patient Dosed in a Phase 1b Trial of IM156 in Pancreatic Cancer

Retrieved on: 
Thursday, November 17, 2022

ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-cancer and anti-fibrotic therapies, today announces that the first patient has been dosed in the single-arm Phase 1b trial of IM156 in combination with gemcitabine and nab-paclitaxel as frontline therapy in patients with advanced pancreatic cancer.

Key Points: 
  • ImmunoMet Therapeutics, Inc., a clinical stage biotechnology company targeting metabolism to develop novel anti-cancer and anti-fibrotic therapies, today announces that the first patient has been dosed in the single-arm Phase 1b trial of IM156 in combination with gemcitabine and nab-paclitaxel as frontline therapy in patients with advanced pancreatic cancer.
  • This clinical trial evaluates the potential of IM156 in combination with gemcitabine and nab-paclitaxel to address resistance and improve patient outcomes.
  • The trial includes a dose escalation phase followed by an expansion phase, treating a total of approximately 25 patients with advanced pancreatic cancer.
  • We are hopeful that this potentially best-in-class OxPhos inhibitor can improve outcomes for these patients, said Dean Welsch, CEO of ImmunoMet Therapeutics.

Nextech AR Announces Updated Proposal To Spin Out Real-World Augmented Reality Spatial Mapping Platform ARitize Maps

Retrieved on: 
Tuesday, July 5, 2022

(Nextech or the Company) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29) announces today that after further consideration, it has determined to pursue a direct spinout of its ARitize Maps platform through a wholly-owned subsidiary of the Company (Subco).

Key Points: 
  • (Nextech or the Company) (OTCQB: NEXCF) (CSE: NTAR) (FSE: N29) announces today that after further consideration, it has determined to pursue a direct spinout of its ARitize Maps platform through a wholly-owned subsidiary of the Company (Subco).
  • In connection with the Arrangement, Nextech intends to seek a direct listing of the Subco Shares on the Canadian Securities Exchange ("CSE").
  • With the ARitize Maps mobile app, anyone can spatially map their location within minutes, and populate it with interactive 3D content, augmented reality navigation, audio, text, images and more.
  • In addition, hackers got access to the ARitize Maps platform, where they used our immersive technology to build their projects.

New Galaxy Book2 Pro Series Enables Work-On-the-Go Flexibility with Peace-of-Mind Security

Retrieved on: 
Sunday, February 27, 2022

MISSISSAUGA, Ontario, Feb. 27, 2022 (GLOBE NEWSWIRE) -- Today, Samsung Electronics Canada announced the launch of the Galaxy Book2 Pro series, a flagship PC lineup featuring the Galaxy Book2 Pro 360 with S Pen functionality and Galaxy Book2 Pro.

Key Points: 
  • MISSISSAUGA, Ontario, Feb. 27, 2022 (GLOBE NEWSWIRE) -- Today, Samsung Electronics Canada announced the launch of the Galaxy Book2 Pro series, a flagship PC lineup featuring the Galaxy Book2 Pro 360 with S Pen functionality and Galaxy Book2 Pro.
  • To further protect users, the Galaxy Book2 Pro series is the first consumer PC lineup meeting Microsofts secured-core PC1 requirements.
  • The Galaxy Book2 Pro series offers the advantages of enterprise security inside an ultra-portable, stylish chassis that easily travels wherever you go.
  • The Galaxy Book2 Pro series advances our ongoing commitment to minimize its environmental footprint and help Galaxy users adopt more sustainable lifestyles.

Regulus Therapeutics Presents Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021

Retrieved on: 
Friday, June 25, 2021

Levels of PC1 and PC2 have previously been shown to be inversely correlated with disease severity.

Key Points: 
  • Levels of PC1 and PC2 have previously been shown to be inversely correlated with disease severity.
  • The poster also describes new data from relevant preclinical models showing treatment with RGLS4326 results in increased gene and polycystin levels in vitro.
  • In addition,improvements in key disease markers including serum creatinine and BUN were demonstrated in the Pkd1(F/RC) mouse model that harbors Pkd1 mutation equivalent to human ADPKD.
  • These and other risks are described in additional detail in Regulus' filings with the Securities and Exchange Commission.

Regulus Therapeutics Collaborates With Bio-Techne For Biomarker Development

Retrieved on: 
Wednesday, December 2, 2020

MINNEAPOLIS, Dec. 2, 2020 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment.

Key Points: 
  • MINNEAPOLIS, Dec. 2, 2020 /PRNewswire/ --Bio-Techne Corporation (NASDAQ: TECH) and Regulus Therapeutics (NASDAQ: RGLS) announced a collaboration to support Regulus with biomarker analysis for the clinical development of RGLS4326, an Autosomal Dominant Polycystic Kidney Disease (ADPKD) treatment.
  • Regulus has utilized two Bio-Techne branded product lines, ProteinSimple and Exosome Diagnostics, to aid in their clinical trial patient testing.
  • Regulus has elected to collaborate with Bio-Techne for the development of high-performance biomarker assays to support the assessment of PC1 and PC2 levels using the fully automated Simple Western instrument as a read-out.
  • "Regulus is pleased to enter this collaboration with Bio-Techne," said Jay Hagan, Chief Executive Officer of Regulus.